Form D · Pharmaceuticals
Moleculin Biotech, Inc.
Houston, TX · CIK 0001659617
Offering snapshot reported May 16, 2016 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 129 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 2, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 16, 2016 | Initial | $6,000,000 | No comparison | 129 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-263286
Based on a value of $6.00 per share, which is the public offering price per share in the company's initial public offering commenced on May 2, 2016.
Source: Form D, filed May 16, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Walter Klemp | Director, Executive |
| Louis Ploth | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2575 West Bellfort Suite 333
Houston, TX, 77054
Houston, TX, 77054